CCSD code C7923 – Intravitreal injection for neovascular AMD

Key takeaways

CCSD Code C7923 covers an intravitreal drug injection for neovascular (wet) AMD only, not dry AMD or other retinal conditions.

Most UK private insurers pay the procedure fee and the drug cost separately, so confirm the drug billing model with each payer.

Most UK private insurers require prior authorization before anti-VEGF injections start. Treating without it is the most common reason C7923 claims are denied.

Injections for central retinal vein occlusion (C7924) or any other indication (C7940) take their own codes, even though the procedure is the same.

Pabau, the practice management platform we build, keeps each injection record, authorization reference and CCSD code together for insurer review.

CCSD Code C7923: Definition and clinical scope

CCSD Code C7923 is the procedure code for an intravitreal injection of a pharmaceutical for neovascular age-related macular degeneration (AMD).

It sits in section 4.10 (Vitreous) of chapter 4, Eye and orbital contents, in the CCSD schedule. The code covers the ophthalmologist’s procedural work: injecting the drug into the vitreous cavity to treat active choroidal neovascularization.

Two points define the code’s scope. First, it applies to neovascular AMD only, so dry AMD without active neovascularization doesn’t qualify. Second, the code doesn’t name a drug. Any agent indicated for neovascular AMD is billed under it, and the drug itself is usually invoiced separately (see the drug cost section below).

US practices bill the same procedure under CPT 67028, which covers an intravitreal drug injection for any indication. CCSD splits that work into three codes by diagnosis, which is why every C7923 claim turns on the AMD diagnosis.

The procedure: Intravitreal injection for neovascular AMD

An intravitreal injection delivers medication straight into the vitreous humor of the eye. That bypasses the blood-retinal barrier, which stops systemic anti-VEGF drugs from reaching therapeutic levels at the macula. The ophthalmologist injects under sterile conditions, usually in an outpatient or treatment room setting.

The steps that support a valid C7923 claim are:

1. Pre-injection OCT imaging to confirm active choroidal neovascularization and document the lesion
2. Visual acuity measurement recorded in the operative note
3. Preparation of the eye with topical anesthetic and povidone-iodine antiseptic
4. Drug drawn from the vial under aseptic technique, with batch number and expiry date recorded
5. Injection through the pars plana (typically 3.5–4 mm from the limbus) using a fine-gauge needle
6. Post-injection intraocular pressure check and fundus examination
7. A completed procedure note documenting laterality, drug name, dose, batch number and post-injection assessment

Each step produces a documentation element that private insurers may ask for when they review a C7923 claim. Leave one out and you risk a request for more information or an outright denial.

Which pharmaceutical agents does C7923 cover?

C7923 covers any pharmaceutical injected intravitreally for neovascular AMD, because it’s a procedure code rather than a drug code. In UK private ophthalmology, the agents in use are four NICE-approved drugs and one off-label option.

If you use newer agents such as faricimab or brolucizumab, confirm acceptance with each insurer before you submit a claim. NICE approval doesn’t guarantee private reimbursement, especially in the first months after a technology appraisal is published.

Drug costs and reimbursement: Is the pharmaceutical included in C7923?

No. Under most UK private insurer contracts, the anti-VEGF drug cost isn’t bundled into the C7923 procedure fee. The procedure fee covers the ophthalmologist’s time, the clinical setting and the injection itself. The drug is usually charged as a separate line on the invoice.

How that drug charge is handled depends on the insurer and the individual policy. The three common models are:

• Pass-through billing: the practice invoices the drug at cost price, and the insurer reimburses at the agreed schedule rate. Bupa and AXA Health typically use this model for approved anti-VEGF agents.
• Insurer-supplied drug: some policies have the insurer or a third-party pharmacy supply the drug directly, which takes the drug cost off the practice invoice entirely.
• Excluded benefit: a minority of policies exclude the drug, leaving the patient to pay for it. This is more common in budget or cash-plan products.

Verify the drug reimbursement model with the insurer before the patient’s first injection. Insurer portals, such as Vitality’s healthcare provider pages and the fee finder inside them, show which charges a policy covers before you raise the invoice.

Neighboring CCSD codes and how to avoid confusion

C7923 is one of seven codes in section 4.10 (Vitreous) of the CCSD procedure codes schedule. Three are drug injections and four are vitrectomies, so the right pick depends on both the procedure and the diagnosis. The vitrectomy codes start with C7910 for anterior vitrectomy and run up to C7982 for vitrectomy with macular surgery.

The codes most often confused with C7923 are its two injection siblings, C7924 and C7940. The procedure is identical, so the confirmed diagnosis decides the code. Neovascular AMD on OCT means C7923, central retinal vein occlusion means C7924, and any other indication, such as diabetic macular edema, means C7940.

The fee won’t catch a wrong pick. On Freedom’s January 2026 schedule, C7923 and C7940 carry the same specialist fee (£350) and anesthetist fee (£142). The error only surfaces when the insurer checks the diagnosis on the claim against the code. The chart below maps each vitreous code to the procedure and diagnosis it covers.

Documentation requirements for C7923

A complete C7923 claim needs documentation that confirms the diagnosis, the decision to treat and the details of the injection. Insurers reviewing anti-VEGF claims look for all of the following in the clinical record:

• Confirmed neovascular AMD diagnosis with OCT evidence of active choroidal neovascularization on, or just before, the injection visit
• Visual acuity measurement at the treatment visit (best-corrected visual acuity in the treated eye, ideally in both eyes)
• Laterality documented explicitly: right eye, left eye or bilateral (both eyes billed separately)
• Drug name, dose and batch number recorded in the procedure note, with the expiry date of the vial
• Operator credentials: the injecting ophthalmologist’s name and GMC number
• Post-injection assessment: intraocular pressure and brief fundus examination findings
• Prior authorization reference number where applicable (see the section below)

Capture this information in structured digital forms at the point of care, not in free-text notes. It then stays easy to retrieve when an insurer asks for evidence. Practices relying on handwritten or unstructured notes often can’t produce the specific data an insurer needs within the response window.

Prior authorization: What payers require before approving C7923

Most UK private health insurers require prior authorization before anti-VEGF injections can go ahead under a C7923 claim. Treatment that starts without a valid authorization reference is almost always denied, however clinically appropriate it was.

The criteria insurers apply to a prior authorization request usually mirror NICE eligibility standards:

• Neovascular AMD confirmed on OCT imaging
• Visual acuity within the treatable range, commonly 6/12 to 6/96 in the affected eye (thresholds vary by insurer and policy year)
• Treatment started or continued by a qualified ophthalmologist or vitreoretinal specialist

Check the current criteria with each insurer, because thresholds are updated periodically.

If you submit several C7923 claims a week, track authorization reference numbers, expiry dates and approved injection counts against each patient record. Authorizations are usually time-limited, for example to six months or a set injection course. Treating past the approved period without renewal is a frequent denial trigger.

Our Bupa CCSD procedure codes guide covers how Bupa lists and pays CCSD-coded procedures. For the request itself, the prior authorization process guide breaks the workflow into steps your team can follow.

Billing C7923 for bilateral injections (both eyes)

When a patient has injections in both eyes in the same session, the billing approach depends on the insurer. UK private payers have no single standard.

The two approaches in use are:

• Two separate C7923 claims: one for the right eye and one for the left, each with laterality documented explicitly. This is the more common model. Some insurers apply a bilateral procedure reduction (typically 50% of the fee for the second eye).
• A single C7923 with a bilateral notation: a minority of insurer contracts specify one claim line with a bilateral indicator. Submitting two claims when the contract specifies one can trigger duplicate-claim denials.

Before billing a bilateral session, get the insurer’s preferred approach in writing. Document the bilateral injection explicitly in the procedure note, with each eye treated and the drug details for each injection. Never assume one insurer’s bilateral rules apply to another.

Common reasons C7923 claims are denied

Anti-VEGF injection claims have more ways to fail than most eye procedure claims. Prior authorization rules, high drug costs and detailed documentation requirements each create a point where a claim can be rejected. The most frequent denial reasons are:

• Missing or expired prior authorization: treatment went ahead before authorization was granted, or after the authorized period lapsed. This is the most common denial trigger for C7923.
• Wrong code selected: C7924 or C7940 submitted instead of C7923. The reverse also fails, with C7923 billed for diabetic macular edema or retinal vein occlusion.
• Insufficient clinical documentation: no OCT evidence, no visual acuity measurement, or laterality missing from the procedure note.
• Drug not on the insurer’s approved formulary: a newer agent (faricimab, brolucizumab) submitted before the insurer has updated its formulary after NICE approval.
• Drug cost invoiced without an agreed pass-through rate: the drug was charged at a rate the insurer hasn’t agreed. Bundling it into the procedure fee fails the same way when a separate line is expected.
• Incorrect eye laterality: the claim states the right eye but the authorization covers the left, or the procedure note doesn’t match the claim form.

Structured medical billing compliance processes, including pre-submission checklists built around each insurer’s requirements, cut the frequency of these denial types.

How to appeal a denied C7923 claim

Most denied C7923 claims are recoverable, provided the clinical basis for treatment is sound and the documentation exists. The appeal follows the same sequence with most UK private insurers.

1. Identify the exact denial reason: request the denial letter or remittance advice and find the specific reason code or narrative. Each denial type needs a different response.
2. Gather the supporting clinical record: pull the OCT report confirming active neovascular AMD and the visual acuity measurement. Add the procedure note with the drug details and batch number. Add the prior authorization reference if the denial concerns missing paperwork rather than a missing authorization.
3. Resubmit with a cover letter: address the denial reason directly and attach any missing documents. For an expired authorization, ask the insurer’s pre-authorization team about retrospective approval before you resubmit.
4. Escalate to provider relations if the first appeal fails: Bupa and AXA Health both have provider relations contacts separate from their claims teams. Bupa’s provider portal includes a formal dispute route, and AXA’s provider relations team is reachable through the AXA Health specialist forms portal.
5. Cite NICE technology appraisals where drug acceptance is disputed: if an insurer won’t recognize a NICE-approved agent, reference the relevant TA in the appeal letter. That’s TA800 for faricimab and TA672 for brolucizumab. Insurers aren’t legally bound by NICE TAs, but they carry weight in appeals as a recognized clinical evidence standard.

Log every appeal with dates, reference numbers and outcomes. Repeated denials on one code or from one insurer usually point to a process problem worth fixing at practice level, rather than claim by claim.

Using Pabau to manage C7923 billing and documentation

Practices billing C7923 every week need the clinical record and the billing workflow in one place, so nobody re-keys injection data into a claim. Pabau’s claims management software lets you attach authorization references to patient records and track claim status across insurers from one workspace.

The features that matter most for anti-VEGF injection billing are:

• Structured procedure records: capture drug name, dose, batch number, laterality and post-injection assessment in set fields. The procedure note is insurer-ready when the appointment closes. Each record sits in the patient’s clinical history.
• Authorization tracking: log prior authorization references, approved injection counts and expiry dates against each patient. Your team can then see a renewal falling due before the next injection.
• CCSD code assignment: apply C7923, or the correct neighboring code, in the appointment record so the wrong code doesn’t reach the claim form.
• Multi-insurer billing: handle the documentation and billing formats that Bupa, AXA, Aviva and other payers require in one system. You no longer keep a manual process per insurer.

Manage C7923 authorizations and records in one place

Pabau helps ophthalmology practices track prior authorization references, store structured injection records, and submit accurate CCSD-coded claims. See how it works for your practice.

Book a demo

Conclusion

C7923 pays reliably when three checks line up before the needle goes in. Confirm neovascular AMD on OCT, so the claim can’t be read as C7924 or C7940. Secure the authorization and note when it expires. Agree with each insurer how the drug is invoiced.

Practices that build those checks into the booking and the procedure note see fewer denials and spend less time on appeals. The trade-off is setting the checks up once per insurer, rather than fixing each claim after it bounces.

Book a demo to see how Pabau keeps C7923 authorizations, injection records and CCSD codes together, so your claims go out complete the first time.

Continue your research

Coding other eye procedures in chapter 4? CCSD code C6920: Paracentesis of the eye walks through billing another common eye procedure under CCSD.

Working on corneal surgery claims? CCSD Code C4620: Lamellar graft to cornea shows how to bill a corneal graft under the CCSD schedule.

Want a structured prior authorization request? Medical prior authorization form gives you a ready-made form for requesting insurer approval before treatment.

Frequently asked questions